b*****h
发帖数: 3386 | 1 http://www.prweb.com/releases/2010PoniardPharmaceutical/01PARD/prweb3443814.htm
New York, NY (PRWEB) January 14, 2010 -
1. PARD will present additional data from their Phase 2 trial using
picoplatin in colorectal cancer (CRC) on January 24, 2010 at the ASCO 2010
Gastrointestinal Cancers Symposium in Orlando, Fla.
Present additional data from the Company's Phase 2 trial... in the first-
line treatment of patients with metastatic colorectal cancer (CRC) on Sunday
, January 24, 2010 at the ASCO 2010 Gastrointestinal Cancers Symposium in
Orlando, Fla
2. PARD will present data from their Phase 2 trial using picoplatin in
prostate cancer on March 5th, 2010.
3. Submit SPEAR efficacy and safety data for the American Society of
Clinical Oncology (ASCO) 2010 Annual Meeting taking place June 4-8, 2010 in
Chicago.
4. A massive short covering rally (with a current 20% - 25% short interest)
may trigger caused by upward momentum from investors.
5. Talks with the FDA for a path forward for picoplatin in small cell lung
cancer (SCLC) in the first half of this year.
6. More updates from trial of an oral formulation of picoplatin, which were
presented in 2009, may also occur during this time.
7. PARD fundamentals: Picoplatin avoids many of the toxicities of the widely
used platinum drugs, which represent an almost $4 billion market in the US.
PARD currently has about $40 million in cash to continue to develop
picoplatin and break into this large market.
8. Technical rally: Technical indicators show that PARD may be oversold (
note again the large short position), with a strong trend of accumulation
and a bullish moving average crossover imminent.
With data from approximately 1,100 patients treated with picoplatin in lung,
colorectal, prostate and ovarian cancers, there is a lot of data available
to suggest the likelihood of its success in clinical trials. |
|
